– Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced that Australian contract research organization (CRO) Novotech has joined Medidata’s ASPire to Win® channel partner program. As the largest full-service Australian CRO, and with an extensive operations footprint across Asia, Novotech can now offer sponsors a full range of services around the Medidata Rave® electronic data capture (EDC) and clinical data management (CDM) solution. Novotech plans to leverage Medidata Rave to streamline the clinical research process for customers conducting Phase I–III trials in nine countries and across a range of therapeutic categories.

Headquartered in Sydney, Novotech works with biotechnology and pharmaceutical companies in North America and Europe to bring new products to the global market by offering a full range of ICH-compliant clinical services, from first human exposure through to completion of Phase III trials. Novotech has helped global customers conduct trials across a population base of more than 1.5 billion people in the Australasian region. As the demand for global clinical outsourcing services continues to grow, Novotech selected Medidata Rave and joined the ASPire to Win program for Medidata’s ability to handle large, complex, global studies and its comprehensive partner enablement program.

Other relevant content